Michael Cremin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Michael Cremin has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Avneel S. Hundal
Harpoon Therapeutics, South San Francisco, California
85 shared publications - Banmeet S. Anand
Harpoon Therapeutics, South San Francisco, California
85 shared publications - Bryan D. Lemon
Harpoon Therapeutics, South San Francisco, California
85 shared publications - Che-Leung Law
Harpoon Therapeutics, South San Francisco, California
85 shared publications - Chi-Heng Wu
Harpoon Therapeutics, South San Francisco, California
85 shared publications - Evan C. Callihan
Harpoon Therapeutics, South San Francisco, California
85 shared publications
Latest Publications
- Open Access
- 23 September 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (39)
Neonatal enteric infection disrupts the microbiota–gut–brain axis through pattern recognition receptors and altered neuroimmune signaling
Early-life enteric infection disrupts the developing microbiota–gut–brain (MGB) axis. Using a neonatal Enteropathogenic Escherichia coli (EPEC) model, we show that intestinal epithelial cell (IEC) nucleotide oligomerization domain (NOD)1 signaling coordinates neuroimmune outcomes throughout early development and into adulthood. Neonatal mice infected at postnatal day (P)7 exhibited ileal inflammation, with increased pro-inflammatory cytokines and monocyte/macrophage infiltration, and loss of myenteric neurons in wild-type mice but not in NOD1 conditional knockout (Nod1 ΔIEC ) mice. These deficits persisted into adulthood (P56), with increased intestinal permeability, sustained inflammatory/repair signatures, neuroinflammation, altered neurogenesis, and impaired recognition memory, which were absent in Nod1 ΔIEC mice, establishing a crucial role for IEC NOD1 in long-term MGB remodeling. Last, bioactive peptidoglycan fragments (muropeptides) were isolated from probiotic Lactobacillus strains and tested as possible therapeutics. Excitingly, supplementation of muropeptides attenuated neonatal EPEC-induced mucosal inflammation and enteric neuron loss without altering bacterial burden, potentially via IEC NOD2. Together, these findings identify IEC NOD-dependent signaling linking early-life enteric infection to enduring gut-brain dysfunction and reveal probiotic-derived muropeptides as candidate therapeutics.
- 23 September 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (39)
Open AccessNeonatal enteric infection disrupts the microbiota–gut–brain axis through pattern recognition receptors and altered neuroimmune signaling
Early-life enteric infection disrupts the developing microbiota–gut–brain (MGB) axis. Using a neonatal Enteropathogenic Escherichia coli (EPEC) model, we show that intestinal epithelial cell (IEC) nucleotide oligomerization domain (NOD)1 signaling coordinates neuroimmune outcomes throughout early development and into adulthood. Neonatal mice infected at postnatal day (P)7 exhibited ileal inflammation, with increased pro-inflammatory cytokines and monocyte/macrophage infiltration, and loss of myenteric neurons in wild-type mice but not in NOD1 conditional knockout (Nod1 ΔIEC ) mice. These deficits persisted into adulthood (P56), with increased intestinal permeability, sustained inflammatory/repair signatures, neuroinflammation, altered neurogenesis, and impaired recognition memory, which were absent in Nod1 ΔIEC mice, establishing a crucial role for IEC NOD1 in long-term MGB remodeling. Last, bioactive peptidoglycan fragments (muropeptides) were isolated from probiotic Lactobacillus strains and tested as possible therapeutics. Excitingly, supplementation of muropeptides attenuated neonatal EPEC-induced mucosal inflammation and enteric neuron loss without altering bacterial burden, potentially via IEC NOD2. Together, these findings identify IEC NOD-dependent signaling linking early-life enteric infection to enduring gut-brain dysfunction and reveal probiotic-derived muropeptides as candidate therapeutics.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S8 from HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
Pharmacokinetic parameters for HPN328 dosed IV in cynomolgus monkeys.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S8 from HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
Pharmacokinetic parameters for HPN328 dosed IV in cynomolgus monkeys.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S15 from HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
TriTAC mediated cytotoxic activity in vitro and in vivo in the hCD3ε mouse model.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S15 from HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
TriTAC mediated cytotoxic activity in vitro and in vivo in the hCD3ε mouse model.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
Antibodies used for immunophenotyping hCD3ε syngeneic model.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
Antibodies used for immunophenotyping hCD3ε syngeneic model.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S7 from HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
EC50 Values for HPN328 induced expression of TNF⍺ and IFNγ.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
EC50 Values for HPN328 induced expression of TNF⍺ and IFNγ.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S17 from HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
HPN328 treatment in cynomolgus monkeys leads to transient reduction in circulating T cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S17 from HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
HPN328 treatment in cynomolgus monkeys leads to transient reduction in circulating T cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S12 from HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
IHC staining of NCI-H82 xenograft tumors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
IHC staining of NCI-H82 xenograft tumors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
EC50 Values from TDCC assays with anti-DLL3 TriTAC in the C:A:T Configuration (HPN328).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
EC50 Values from TDCC assays with anti-DLL3 TriTAC in the C:A:T Configuration (HPN328).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S14 from HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
Stimulation with anti-human CD3 and anti-mouse CD28 beads induces proliferation and activation of T cells from hCD3ε mice.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S14 from HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
Stimulation with anti-human CD3 and anti-mouse CD28 beads induces proliferation and activation of T cells from hCD3ε mice.